Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study

Abstract

The influence of optimal medical treatment (OMT) with or without additional percutaneous transluminal angioplasty (PTA) on vascular inflammation in peripheral arterial occlusive disease (PAD) patients was investigated. Patients with intermittent claudication (IC) and angiographically verified PAD were randomized to OMT (n = 28) or OMT + PTA (n = 28) and followed for 12 months. Ankle—brachial index (ABI), treadmill walking distances (WD), visual analogue scale (VAS), and blood sampling for the determination of selected soluble biomarkers were undertaken at baseline and after 3 and 12 months. After both 3 and 12 months, ABI, WD and VAS were highly significantly improved in favour of OMT + PTA (p < 0.05 for all). Significant improvements were recorded in both groups in serum lipids (p < 0.01 for all), except for triglycerides, and in the inflammatory markers P-selectin, interleukin-6, interleukin-10, monocyte chemoattractant protein-1 and fibrinogen (p < 0.05 for all). There were, however, no differences in the changes from baseline between the groups in any variable. Intervention with OMT alone or in combination with PTA did not differ with regard to the effects on serum lipids and markers of inflammation in our population of PAD patients. The combined treatment was, however, better for the treadmill walking distance.

Keywords

cytokines inflammation optimal medical treatment (OMT)percutaneous transluminal angioplasty (PTA)peripheral arterial occlusive disease (PAD)

References

Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med 1999; 340: 115—26.

Libby P. , Ridker PM , Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135—43.

Szmitko PE , Wang CH , Weisel RD New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108: 1917—23.

Ridker PM , Cannon CP , Morrow D. , Rifai N. , Rose LM C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20—28.

Blankenberg S. , Rupprecht HJ , Bickel C. , Peetz D. , Hafner G. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336—42.

Hwang SJ , Ballantyne CM , Sharett AR , Smith LC , Davis CE Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 4219—25.

Danesh J. , Wheeler JG , Hirschfield GM , Eda S. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004 ; 350: 1387—97.

Fowkes FGR , Housley E. , Cawood EHH , MacIntyre CCA , Ruckley CV , Prescott RJ Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 383—92.

Dormandy JA , Mahir M. , Ascady G. et al. The fate of the claudicant — a prospective study of 1969 claudicants. J Cardiovasc Surg (Torino) 1989; 30: 50—57.

10.

Selvin E. , Erlinger TP Prevalence of and risk factors for peripheral arterial disease in the United States. Circulation 2004; 110: 738—43.

11.

Smith I. , Franks PJ , Greenhalgh RM , Poulter NR , Powell JT The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischemia . Eur J Vasc Endovasc Surg 1996; 11: 402—408.

12.

Fowkes FG , Housley E. , Riemersma RA , Macintyre CC Smoking, lipids, glucose in-tolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992 ; 135: 331—40.

13.

Drexel H. , Steurer J. , Muntwyler J. , Meienberg S. Predictors of the presence and extent of peripheral arterial occlusive disease . Circulation 1996; 94(suppl 1): II-199—205.

14.

Willegendael EM , Tejink JAW , Barteling ML Influence of smoking on the incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004; 40: 1158—65.

15.

Hughes JR , Stead LF , Lancaster T. Adjunctive measures such as nicotine replacement therapy (NRT) and Bupropion have shown to make permanent smoking cessation more successful. Cochrane Database Sys Rev 2003; 2: CD0000031.

16.

Housley E. Treating claudication in five words. Br Med J 1988; 296: 1483—84.

17.

Gardner AW , Poehlman ET Exercise rehabilitation programs for the treatment of claudication pain. JAMA 1995; 274: 975—80.

18.

Hart RG , Halperin JL , McBride R. , Benavente O. Aspirin for the primary prevention of stroke and other major vascular events . Arch Neurol 2000; 57: 326—32.

19.

Dormandy JR , Rutherford RB Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic Inter-Society Consensus (TASC) . J Vasc Surg 2003; 31: S1—296.

20.

Nylænde M. , Abdelnoor M. , Stranden E. et al. The Oslo balloon angioplasty versus conservative treatment study (OBACT). The 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2006; 33: 3—12.

21.

Karnath B. Smoking cessation. Am J Med 2002; 112: 399—405.

22.

Hughes JR , Stead LF , Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2003; 2: CD00031.

23.

Ashworth NL , Chad KE , Harrison EL , Reeder BA , Marshall SC Home vs center based physical activity programs in older adults. The Cochrane Database Syst Rev 2005; 1: CD004017.

24.

Laws PE , Spark JI , Cowled PA , Fitridge RA The role of statins in vascular disease. Review. Eur J Vasc Endovasc Surg 2004; 27: 6—16.

25.

Capek P. , McLean GK , Berkowitz HD Femoropopliteal angioplasty. Factors influencing long-term success . Circulation 1991; 83(2 suppl): 70.

26.

Klein WM , Graaf Y. , Seegers J. et al. (The Dutch Iliac Stent Trial Study Group.) Dutch iliac stent trial: long-term results in patients randomised for primary or selective stent placement. Radiology 2006; 238: 734—44.

27.

Sapoval MR , Long AL , Raynaud AC , Beyssen MB , Fiessinger JN , Gaux JC Femoropopliteal stent placement. Long-term results. Radiology 1992; 184: 833—39.

28.

Myers C. , Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatique syndrome . Qual Life Res 1999; 8: 9—16.

29.

Nylænde M. , Kroese A. , Stranden E. et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 2006; 11: 21—28.

30.

Clauss A. Gerinnungsphysiologische Schnellmetode zur Bestimmung des Fibrinogens . Acta Haematol 1957; 17: 237—46.

31.

Ueno H. , Pradhan S. , Schlessel D. , Hirasawa H. , Sumpio BE

Nicotine enhances human vascular endothelial cell expression of ICAM-1 and VCAM-1 via protein kinase C, p38 mitogenactivated protein kinase NF-kappaB, and AP-1. Cardiovasc

Toxicol 2006; 6: 39—50.

32.

Frolich M. , Sund M. , Lowel H. , Imhof A. , Hoffmeister A. , Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24: 1365—72.

33.

Colbert LH , Visser M. , Simonsick EM et al. Physical activity, exercise, and inflammatory markers in older adults: findings from the Health Aging and Body Composition Study. J Am Geriatr Soc 2004; 52: 1098—104.

34.

Reuben DB , Judd-Hamilton L. , Harris TB et al. The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur Studies of Successful Ageing. J Am Geriatr Soc 2003; 51: 1125—30.

35.

Hammett CJ , Prapavessis H. , Baldi JC et al. Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk. Am Heart J 2006; 151: 367.e7-16.

36.

Nylænde M. , Kroese A. , Stranden E. et al. Prothrombotic activity is associated with the anatomical as well as the functional severity of peripheral arterial occlusive disease. Thromb Haemost 2006; 95: 702—07.

37.

Rollins BJ Chemokines. Blood 1997; 90: 909—28.

38.

Krishnaswamy G. , Kelley J. , Yerra L. , Smith JK Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999; 19: 91—104.

39.

Yang YY , Hu CJ , Chang SM , TaiTY , LeuSJ Aspirin inhibits monocyte chemoattractant protein-1 and interleukin-8 expression in TNF-alpha stimulated human umbilical vein endothelial cells . Atherosclerosis 2004; 174: 207—13.

40.

Zimmerman MA , Reznikov LL , Raeburn CD , Selzman CH Interleukin-10 attenuates the response to vascular injury. J Surg Res 2004; 121: 206—13.

41.

Waehre T. , Halvorsen B. , Damas JK et al. Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002; 32: 803—10.

42.

Seljeflot I. , Hurlen M. , Solheim S. , Arnesen H. Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction. J Thromb Haemost 2004; 2: 350—52.

43.

Cominacini L. , Rigoni A. , Fratta Pasini A et al. The binding of oxidized low-density lipoprotein (ox-LDL) to ox-LDL receptor-1 in endothelial cells reduces the intracellular concentration of nitric oxide through an increased production of superoxide. J Biol Chem 2001 ; 276: 13,750—55.

44.

Shimada K. , Mokuno H. , Matsunaga E. et al. Circulating oxidised low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 2004; 174: 343—47.

45.

Halvorsen B. , Waehre T. , Scholz H. et al. Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms . J Lipid Res 2005; 46: 211—19.

46.

Waters DD What the statin trials have taught us. Am J Cardiol 2006; 98: 129—34.

47.

Mora S. , Ridker PM

Justification for the use of statins in primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) — can C-reactive protein be used to target statin therapy in primary prevention?

Am J Cardiol 2006; 97: 33A—41A.

48.

Koenig D. , Deibert P. , Winkler K. , Berg A. Association between LDL-cholesterol, statin therapy, physical activity and inflammatory markers in patients with stable coronary heart disease. Exerc Immunol Rev 2005; 11: 97—107.

49.

Seljeflot I. , Tonstad S. , Hjermann I. , Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002 ; 162: 179—85.

50.

Solheim S. , Seljeflot I. , Arnesen H. , Eritsland J. , Eikvar L. Reduced levels of TNFα in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 2001; 157: 86—91.